Pharma Foods International Co., Ltd. (2929) AI Stock Analysis

• Market Cap: ¥19.44B
• Dividend Yield: 3.65%
• Average Volume (3M): 110.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: 9.53%
• EPS Growth: -155.76%
• Country: JP
• Employees: 642
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -65.52
• Shares Outstanding: 29,079,000
• 10 Day Avg. Volume: 122,950
• 30 Day Avg. Volume: 110,460
• PEG Ratio: -0.78
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 0.39
• P/FCF Ratio: -12.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ¥676.00 ▼(-0.44% Downside)

Pharma Foods International's overall stock score is primarily impacted by its financial performance and technical analysis. The company's positive revenue growth is overshadowed by declining profitability and cash flow issues. Technical indicators suggest bearish momentum, further weighing down the score. The valuation is concerning due to a negative P/E ratio, though the dividend yield provides some appeal.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for the company's products and effective market strategies, supporting long-term business expansion.

Improved Leverage

Reduced leverage enhances financial stability and flexibility, allowing the company to better manage economic fluctuations and invest in growth opportunities.

Strong Gross Profit Margin

A strong gross profit margin suggests effective cost control and pricing strategies, providing a buffer against operational cost increases and supporting profitability.

Negative Factors

Declining Profitability Margins

Declining profitability margins may indicate rising costs or pricing pressures, which can erode earnings and affect long-term financial health.

Cash Flow Issues

Cash flow issues can limit the company's ability to invest in growth and meet financial obligations, posing risks to operational stability and expansion plans.

Decreased Return on Equity

A decrease in return on equity indicates less efficient use of shareholder funds, potentially impacting investor confidence and future capital raising efforts.

Pharma Foods International Co., Ltd. Business Overview & Revenue Model

Company Description

Pharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. Its products include Pharma-GABA, Bonepep, Ovopron (egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg, as well as iHA, a substance that stimulates secretion of hyaluronic acid. Pharma Foods International Co., Ltd. has licensing agreement with Mitsubishi Tanabe Pharma Corporation for a new therapeutic antibody to treat autoimmune diseases. Pharma Foods International Co., Ltd. was founded in 1997 and is based in Kyoto, Japan.

How the Company Makes Money

Pharma Foods International Co., Ltd. generates revenue primarily through the sale of its dietary supplements and functional food products. The company employs a multi-channel distribution strategy that includes direct sales, e-commerce platforms, and partnerships with healthcare providers and retail outlets. Key revenue streams include bulk sales to distributors, retail product sales, and subscription-based models for recurring customers. Additionally, the company may engage in collaborative partnerships with other healthcare firms for co-development projects, which can provide significant income through joint marketing efforts and shared research initiatives.

Pharma Foods International Co., Ltd. Financial Statement Overview

Summary

Pharma Foods International shows mixed financial performance. Revenue growth is positive, but declining profitability and cash flow challenges pose significant risks. The balance sheet indicates improved leverage, yet cash flow issues need urgent attention to ensure long-term stability.

Income Statement

Pharma Foods International has shown a consistent revenue growth trend, with a notable 5.6% increase in the latest year. However, profitability margins have declined, with the net profit margin dropping significantly from 5.16% to 0.56%. The gross profit margin remains strong at over 80%, indicating efficient cost management. The decline in EBIT and EBITDA margins suggests increased operational costs or reduced pricing power.

Balance Sheet

The company's debt-to-equity ratio has improved from 2.38 to 1.09, indicating a reduction in leverage and a more balanced capital structure. However, the return on equity has decreased significantly, reflecting lower profitability. The equity ratio remains stable, suggesting a solid asset base relative to equity.

Cash Flow

Pharma Foods International's cash flow situation is concerning, with negative operating and free cash flows in the latest period. The free cash flow to net income ratio is high, indicating cash flow issues despite reported profits. The company needs to improve cash generation to support operations and growth.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	65.26B	62.15B	68.57B	60.19B	46.75B
Gross Profit	52.58B	48.75B	55.28B	48.11B	39.73B
EBITDA	3.15B	6.00B	4.16B	1.97B	5.96B
Net Income	368.00M	3.21B	3.08B	-374.00M	3.84B
Balance Sheet
Total Assets	32.65B	36.57B	36.23B	31.16B	20.94B
Cash, Cash Equivalents and Short-Term Investments	9.16B	15.67B	16.31B	8.85B	9.79B
Total Debt	12.63B	16.89B	20.10B	16.86B	4.90B
Total Liabilities	21.10B	24.99B	26.60B	24.09B	12.48B
Stockholders Equity	11.55B	11.59B	9.63B	7.07B	8.46B
Cash Flow
Free Cash Flow	-1.98B	4.51B	5.72B	-6.54B	5.76B
Operating Cash Flow	-1.09B	5.49B	6.13B	-6.07B	5.94B
Investing Cash Flow	-950.00M	-1.39B	-1.01B	-2.54B	-442.00M
Financing Cash Flow	-4.47B	-4.84B	2.34B	7.68B	1.03B

Pharma Foods International Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 679.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2929, the sentiment is Neutral. The current price of 679 is above the 20-day moving average (MA) of 670.98, below the 50-day MA of 692.84, and below the 200-day MA of 818.03, indicating a neutral trend. The MACD of -7.11 indicates Negative momentum. The RSI at 47.41 is Neutral, neither overbought nor oversold. The STOCH value of 21.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2929.

Pharma Foods International Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4554	71 Outperform	¥46.60B	15.52	6.49%	2.39%	12.01%	-51.38%
4574	63 Neutral	¥14.27B	16.78	―	―	-5.41%	―
4577	63 Neutral	¥40.14B	17.94	―	2.75%	7.56%	-48.91%
4538	60 Neutral	¥19.93B	-4.86	―	3.71%	7.50%	-281.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4512	48 Neutral	¥10.72B	148.66	―	1.06%	5.42%	-62.03%
2929	47 Neutral	¥19.44B	-10.34	―	3.65%	9.53%	-155.76%

Pharma Foods International Co., Ltd. Corporate Events

Pharma Foods International Reports Increased Sales but Faces Profit Decline

Pharma Foods International Co., Ltd. reported its consolidated financial results for the three months ended October 31, 2025, showing a year-on-year increase in net sales by 7.6% to ¥15,712 million. However, the company experienced a significant decline in profitability, with an operating loss of ¥2,511 million and a net loss of ¥1,891 million. This downturn in profits is attributed to various factors affecting the company’s operations, impacting its financial health and potentially influencing its market position.

The most recent analyst rating on (JP:2929) stock is a Hold with a Yen916.00 price target. To see the full list of analyst forecasts on Pharma Foods International Co., Ltd. stock, see the JP:2929 Stock Forecast page.

Pharma Foods Announces Treasury Shares Disposal for Stock Compensation

Pharma Foods International Co., Ltd. announced the disposal of treasury shares as restricted stock compensation to its directors and executive officers. This move aims to align the interests of the company’s leadership with shareholders by tying compensation to stock performance, thereby enhancing motivation and potentially improving corporate value.

The most recent analyst rating on (JP:2929) stock is a Hold with a Yen916.00 price target. To see the full list of analyst forecasts on Pharma Foods International Co., Ltd. stock, see the JP:2929 Stock Forecast page.